Relatively sparse. Most neuropathies were the literature on neuropathy itself was a study of neuropathy. Until 60 years ago, the phenomenon slowly emerged through the nervous system. Early concepts of paraneoplastic disorders is relatively recent in the clinical neurosciences, and one that remains incompletely understood to this day, particularly in terms of therapy. By means of definition, paraneoplastic disorders have tended to encompass all remote effects of cancer, not attributable to metastases, treatment or the presence of coexistent illness. In terms of disease pathophysiology, the cause of paraneoplastic disorders has been linked to a specific, painful, sensory ataxic syndromes. Denny-Brown’s paper that launched a concept for paraneoplastic phenomena began by describing two cases (one a boiler cleaner and the other a retired Army Colonel) in which both had initially presented with rapidly progressive, painful, sensory ataxic syndromes. On neurological examination, both patients displayed ataxia, severely reduced sensation and reduced or absent reflexes. Both died within 8 months. Subsequent autopsy identified a severe loss of dorsal root ganglion cells as the cause of neuropathy and the unexpected presence of bronchogenic carcinoma. Specifically, Denny-Brown described the severe loss of nerve cells in the dorsal root ganglia without corresponding change in the ventral roots and concluded that the similarity of clinical phenotype in these two patients suggested that the presence of carcinoma was more than just a chance occurrence.

Possible causes of the neuropathic symptoms raised at the time of the Denny-Brown study included tumour invasion into the lymphatics of the peripheral nerves and invasion into intrathecal portions of the spinal nerves, in addition to potential toxic and metabolic pathways. Denny-Brown ended by suggesting that the cause of the neuropathy was likely ‘the result of a nervous reflex from the lung’. He further surmised that the cancer may have triggered a metabolic disorder and likened the presentations to vitamin deficiencies, akin to animals afflicted with vitamin E deficiency.

The description of a connection between neuropathy and a coexistent carcinoma has in turn linked Denny-Brown to the syndrome of sensory ganglionopathy associated with cancer. Subsequent studies have more precisely identified the cause of this specific syndrome to circulating auto-antibodies (anti-Hu) directed against intracellular antigens present in the dorsal root ganglion cells. Further clinical research has greatly expanded our understanding of these paraneoplastic syndromes more generally, with the unifying feature linked to an immune-mediated pathogenesis. Distinct antigens have led to classifications based around clinical phenotypes and associated autoantibody production and also through the location of the antigen, being either intracellular or extracellular. In addition, there can be overlap with similar syndromes which may develop in the absence of an identifiable cancer. In those syndromes with autoantibodies that target intracellular antigens, cancer is almost always present.

While there has been improved understanding in disease pathophysiology, treatment approaches still often remain uncertain. Some disorders such as the Lambert-Eaton myasthenic syndrome and myasthenia gravis may respond well to immunosuppression and to treatment of the underlying tumour. In contrast, encephalomyelitis associated with cancer and paraneoplastic cerebellar degeneration usually respond poorly to treatment. Differences in cellular and humoral immunity, as well as the nature of autoantibody target antigens such as receptors and ion channels, likely underlie these differential responses to therapy. While the field of paraneoplastic neurology has certainly advanced since the original JNNP landmark study, as Denny-Brown wisely concluded then, more studies on similar cases in the future are indicated to better unlock the precision therapies that will no doubt be required.

Twitter Matthew C Kiernan @jnnp_bmj
Funding  The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests  None declared.

Patient consent for publication  Not required.

Provenance and peer review  Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

To cite  Kiernan MC, Cornblath DR. J Neurol Neurosurg Psychiatry 2020;91:793–794.

Received 6 March 2020
Accepted 11 March 2020
Published Online First 3 April 2020

J Neurol Neurosurg Psychiatry 2020;91:793–794.
doi:10.1136/jnnp-2020-323171

REFERENCES